Think of it as radical bio-intelligence
We combine artificial intelligence with automation to conduct experimental biology at scale — testing thousands of compounds on hundreds of cellular disease models in parallel. Our embrace of systems biology and our commitment to an unbiased approach are leading to novel discoveries. With every experiment, our system gets smarter.
We’re aiming for 100 new treatments by 2025
We know this sounds improbable, but we wanted ambitious goals to stretch ourselves further, force ourselves to question assumptions, and move faster. The results in our pipeline indicate we are onto something. Look at the data with us.
“Deep learning has recently proven capable of driving cars, beating the world champion of the game of Go, translating from one language to another and recognizing faces dramatically better than any previous efforts to date. Recursion is taking this success and applying it to millions of high-resolution cellular images, with a high potential to make biological discoveries with a medical impact and breadth never seen before.”
Recursion Scientific Advisor
The latest news
Articles and Press Releases
08.29.17
Machine Vision Helps Spot New Drug Treatments
A startup uses algorithms that understand the anatomy of cells to discover new uses for existing drugs.
08.17.17
How a start-up has found a dozen treatments for rare diseases using robots
Cerebral cavernous malformation isn't the kind of disease the average person is familiar with. But for the 0.5 percent of the population afflicted with the genetic affliction — which causes blood vessels in the brain to grow irregularly — every day can be terrifying.
08.10.17
10 AI Health Care Companies to Follow in 2017
The medical field is going through an evolution — and artificial intelligence is powering its push.
